

1 **Pregnancy and breastfeeding during COVID-19 pandemic: A systematic review of**
2 **published pregnancy cases**

3

4 **Authors**

5 Carina RODRIGUES, MSc*

6 EPIUnit – Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.

7

8 Inês BAÍA, MPH*

9 EPIUnit – Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.

10

11 Rosa DOMINGUES, PhD

12 Instituto Nacional de Infectologia Evandro Chagas / Fundação Oswaldo Cruz, Rio de

13 Janeiro, Brasil

14

15 Henrique BARROS, MD, PhD

16 EPIUnit – Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.

17 Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade

18 de Medicina, Universidade do Porto, Porto, Portugal.

19

20 * Equal contribution

21

22 **Corresponding author**

23 Carina Rodrigues

24 Instituto de Saúde Pública da Universidade do Porto

25 Rua das Taipas, 135, 4050-600 Porto, Portugal

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 E-mail: carina.rodrigues@ispup.up.pt

27 Phone: (+351) 222061820

28

29 **Disclosure statement**

30 The authors report no conflict of interest.

31

32 **Funding**

33 This study was funded by national funding from the Foundation for Science
34 and Technology – FCT (Portuguese Ministry of Science, Technology and Higher
35 Education), the Operational Programmes Competitiveness and Internationalization
36 (COMPETE 2020) and Human Capital (POCH), Portugal 2020, under the Unidade de
37 Investigação em Epidemiologia - Instituto de Saúde Pública da Universidade do Porto
38 (EPIUnit) (POCI-01-0145-FEDER-006862; UID/DTP/04750/2019) and the PhD grant
39 SFRH/BD/111794/2015 (CR).

40

41 **Word count abstract:** 293

42 **Word count main text:** 2852

43

44 **Short title**

45 COVID-19: impact on pregnancy and breastfeeding

46

47 **A. Why was this study conducted?**

48 Pregnant women and newborns are exposed to COVID-19 and at risk for adverse
49 outcomes. The review of evidence is essential to guide preventive action and therapy.

50 **B. What are the key findings?**

51 Fetal distress and preterm delivery seem to be more frequent among COVID-19 pregnant
52 women. Also, evidence on vertical transmission is emerging but the clinical relevance of
53 the fetal infection remains unclear. No evidence links the SARS-CoV-2 virus to
54 transmission via breast milk.

55 **C. What does this study add to what is already known?**

56 The comprehensive review of 212 pregnant women with COVID-19, summarizes the
57 evidence on vertical transmission, as well as adverse maternal and neonatal outcomes.
58 Additionally, it adds the characteristics of the first eight cases of COVID-19 positive
59 women delivered in Portugal.

60

61 **Abstract**

62 **Background:** The COVID-19 pandemic is an emerging concern regarding the potential
63 adverse effects during pregnancy. This study reviews knowledge on the impact of
64 COVID-19 on pregnancy and describes the outcome of published cases of pregnant
65 women diagnosed with COVID-19, as well as the characteristics of COVID-19 positive
66 women who delivered in Portugal by 31 of March 2020.

67 **Methods:** Searches were conducted in PubMed® up to 8 April 2020, using PRISMA
68 standards, to identify original published studies describing pregnant women at any
69 gestational age diagnosed COVID-19. There were no date or language restrictions on the
70 search. All identified studies were included irrespective of assumptions on study quality.
71 Portuguese cases were ascertained by contact with all Portuguese maternities and based
72 on the information provided by their health professionals.

73 **Results:** We identified 30 original studies reporting 212 cases of pregnant women with
74 COVID-19 (30 discharged while pregnant), 200 from China and 12 from other countries.
75 The 182 published deliveries resulted in one stillbirth and 185 live births. Four women
76 with severe COVID-19 required admission to an intensive care unit but no cases of
77 maternal death were reported. There was one neonatal death. Preterm births occurred in
78 28.7% of cases, but it is unclear whether this was iatrogenic. All cases with amniotic fluid,
79 placenta, and/or cord blood analyzed for the SARS-CoV-2 virus were negative. Four
80 newborns were positive for SARS-CoV-2 and three newborns had high levels of IgM
81 antibodies. None of the first eight infants born in Portugal tested positive. Breast milk
82 samples from 13 mothers and described in seven studies showed no evidence of SARS-
83 CoV-2.

84 **Conclusion:** The evidence related to the effect of COVID-19 on pregnant women is still
85 limited. Pregnant women and newborns should be considered particularly vulnerable
86 populations regarding COVID-19 prevention and management strategies.

87

88 **Keywords:**

89 COVID-19, SARS-COV-2, Pregnancy, Vertical transmission, Breastfeeding, Perinatal
90 outcomes, systematic review.

91 **Introduction**

92 The disease resulting from infection with the Severe Acute Respiratory Syndrome
93 Coronavirus 2 (SARS-COV-2) and designated COVID-19 by the World Health
94 Organization (WHO) was first identified in humans in December 2019, in the city of
95 Wuhan, China,¹ and can present from asymptomatic to a severe acute respiratory infection
96 requiring intensive care.^{2, 3} The infection can occur at any age, but COVID-19 is
97 proportionally uncommon in children (<1% of the total cases). The infection fatality rate
98 is around 1% but much higher in older people or those with pre-existing medical
99 conditions (such as heart disease, diabetes, COPD).^{2, 4}

100 Person-to-person transmission of COVID-19 is well established and can occur when an
101 infected person coughs, sneezes or speaks and scattered droplets are inhaled or reach the
102 mucous membranes of the mouth, nose or eyes of susceptible. COVID-19 can also be
103 transmitted through direct hand contact with surfaces or objects contaminated with
104 SARS-CoV-2 followed by contact with the mouth, nose or eyes.²

105 Pregnant women and newborns receive special attention and there is an emerging concern
106 with the potential risk of SARS-COV-2 vertical transmission (from mother to fetus) or
107 associated malformations, and contagion during delivery and breastfeeding; likewise, it
108 is important to determine the potential adverse effects of COVID-19 in pregnant women.⁵⁻

109 ⁸ However, in general, the available information remains scarce.

110 This study reviews published cases of pregnant women diagnosed with COVID-19 and
111 presents the characteristics of the first cases of COVID-19 positive women who delivered
112 in Portugal as identified by the 31st of March 2020.

113

114

115

116 **Methods**

117 The review follows the Preferred Reporting of Systematic Reviews and Meta-Analysis
118 (PRISMA) guidelines.^{9, 10}

119 We searched PubMed® up to 8 April 2020 to identify original published studies
120 describing pregnant women at any gestational age diagnosed with COVID-19 (confirmed
121 by clinical/radiological evidence of pneumonia compatible with SARS-CoV-2 and/or by
122 quantitative real-time polymerase chain reaction (PCR) or dual fluorescence PCR of
123 SARS-CoV-2 infection). The following search expression was used [(COVID-19 OR
124 2019-nCoV OR "novel coronavirus" OR SARS-CoV-2 OR "coronavirus 2") AND
125 (pregnancy OR delivery OR pregnant OR obstetric* OR maternal OR perinatal OR
126 breastfeeding)]. Also, reference tracking was carried out to identify other potential studies
127 to be included.

128 Each reference retrieved was screened independently by two researchers (IB and RD)
129 following predefined criteria to determine eligibility for the systematic review. Studies
130 were excluded if: (1) did not involve humans (e.g. in vitro or animal research); (2) non-
131 original articles (e.g. book chapters, review articles, editorials, comments, guidelines); (3)
132 data not reporting pregnant women diagnosed with COVID-19; and (4) duplicate studies
133 or evaluating the same sample. There were no date or language restrictions on the search.
134 Two researchers (IB and RD) reviewed the included studies and extracted the following
135 data: collection period, maternal age, pregnancy complications, type of delivery,
136 indication for cesarean section, gestational age at birth (or at admission), pregnancy
137 outcome, maternal admission to intensive care unit, maternal death, neonatal outcomes
138 (birth weight, Apgar at 1 and 5 minutes, neonatal complications, breastfeeding),
139 intrauterine and/or neonatal samples collected for detection of SARS-CoV-2 (such as

140 amniotic fluid, cord blood, placenta, breast milk, nasopharyngeal and anal swabs) and
141 their results (negative/positive).

142 All identified original studies reporting cases of pregnant women at any gestational age
143 diagnosed with COVID-19 were included irrespective of study quality. Cases reported in
144 more than one study, and for which it was possible to identify duplicates, were described
145 only once, presenting the more detailed data. We identified duplicates based on author
146 names and hospital location, publication date, participant admission date, maternal and
147 neonatal characteristics and outcomes.

148 Doubts on possible duplicates and/or differences in the data extraction were discussed
149 and resolved by consensus, involving a third researcher (CR) whenever necessary.

150 Cases of COVID-19 positive women delivered in Portugal by the 31st of March 2020 were
151 identified, according to the information reported by health professionals. Information on
152 sex, gestational age (completed weeks), type of delivery, birth weight and the presence
153 of SARS-CoV-2 on the infant was collected.

154

159 **Results**

160 Table 1 summarizes the main characteristics of the 212 reported cases of pregnant women
161 diagnosed with COVID-19 and identified in 30 original studies published until April 8,
162 2020. A detailed description of each reported case is presented in Table S1 (supplemental
163 material).

164 All published cases occurred in China, except eight from the United States of America,¹¹,
165 ¹² one from South Korea,¹³ one from Honduras,¹⁴ one from Turkey,¹⁵ and another from
166 Sweden.¹⁶ Maternal age ranged from 22 to 41 years. From the 212 pregnant women
167 described, 182 delivered and 30 were discharged during pregnancy (undelivered). Most

168 women were in the third trimester of pregnancy and there was only one study reporting
169 pregnant women in the first trimester.¹⁷

170 Table 2 describes the characteristics of the first eight cases of COVID-19 positive women
171 delivered in Portugal, until the 31st of March 2020.

172

173 **Vertical transmission of COVID-19**

174 All cases in which amniotic fluid, placenta, and/or cord blood were analyzed for SARS-
175 CoV-2 virus were negative.^{5, 11, 13, 15, 18-26}

176 Most studies detected the SARS-CoV-2 RNA by real-time reverse transcription-
177 polymerase chain reaction (RT-PCR) using samples from the newborn's nasopharyngeal
178 or throat, sample collection varying from immediately to 9 days after birth. Two studies
179 also used maternal and neonatal sera samples to test for IgG and IgM antibodies.^{27, 28}

180 Four newborns (2.2%) presented positive oral swabs for SARS-CoV-2.^{21, 24, 25, 29} In a
181 cohort of 33 newborns from mothers with COVID-19, admitted to the Pediatric Hospital
182 of Wuhan, three of the newborns had positive RT-PCR for SARS-CoV-2 in
183 nasopharyngeal and anal swabs collected on the second and fourth days after delivery,
184 with negative results on the sixth day for two newborns and on the seventh day for
185 another. However, placenta, amniotic fluid, and cord blood samples were not analyzed.²⁹

186 There is yet another case of a newborn with a positive RT-PCR for SARS COV-2 in one
187 throat swab collected at 36 hours after birth.^{21, 24} However, it was not possible to confirm
188 whether it was a real case of intrauterine transmission since the umbilical cord and
189 placenta blood samples were negative for SARS-CoV-2 and the possibility of postnatal
190 contact could not be discarded.^{21, 24} No other study reported positive results for the SARS-
191 CoV-2 virus in nasopharyngeal exudates from newborns of mothers diagnosed with

192 COVID-19.^{5, 11-20, 22-26, 29-36} None of the first eight infants born in Portugal tested positive
193 for the SARS-CoV-2 virus (Table 2).

194 In a series of six cases that had blood collected after delivery evaluated, two of the
195 newborns had high levels of IgG and IgM antibodies (>10 AU/mL) and three had high
196 values of IgG antibodies with normal levels of IgM in, but in none SARS-CoV-2 virus
197 was detected by RT-PCR in the oropharyngeal exudate.²⁷ A case study also reported high
198 values of IgM and IgG antibodies in the blood at days 1 and 15 after delivery, but with
199 RT-PCR for SARS-CoV-2 negative in five samples of nasopharyngeal exudates collected
200 between the first two hours and the 16th day of life.²⁸

201 Seven studies reported the test of breast milk samples from 13 mothers and none
202 evidenced SARS-CoV-2 virus.^{5, 15, 16, 20-22, 28}

203

204 **Maternal and neonatal outcomes**

205 The clinical and obstetric conditions most frequently reported were fetal distress (n=20),
206 gestational diabetes (n=13), gestational hypertension (n=11), premature rupture of
207 membranes (PROM) (n=7), anemia (n=5), placenta previa/bleeding in the third trimester
208 (n=5), pre-eclampsia (n=4), hypothyroidism (n=4), chronic hypertension (n=3),
209 thalassemia(n=2), polycystic ovary syndrome (n=2), cholecystitis (n=2), asthma (n=2),
210 diabetes mellitus type 2 (n=2), placental abruption (n=1), oligohydramnios(n=1),
211 polyhydramnios (n=1), hepatitis B infection (n=1) and mitral valve and tricuspid valve
212 replacement (n=1). In one study that compared groups of pregnant women with and
213 without COVID-19, there were no significant differences in the occurrence of gestational
214 diabetes, severe pre-eclampsia, PROM, fetal distress, meconium-stained amniotic fluid,
215 premature delivery, neonatal asphyxia and procedures for severe post-partum bleeding.³⁰

216 Cesarean section was the most common type of delivery: 88.0% of 158 cases with
217 available information. This was also observed in Portuguese cases in which 6 (75%) were
218 born by cesarean. Most studies did not specify the indication for the cesarean section.
219 Four pregnant women with severe COVID-19 required admission to an intensive care
220 unit: one at 30 weeks of gestation, after an emergency cesarean section;¹⁹ another case at
221 34 weeks of gestation that resulted in an emergency cesarean for a stillbirth;³¹ and other
222 two cases at 37 weeks of gestation of women with high BMI (>35) and history of medical
223 complications, admitted for labor induction.¹² No maternal deaths from COVID-19 were
224 published.

225 The 182 deliveries resulted in one stillbirth (intrauterine fetal death)³¹ and 185 live births
226 (four twin pregnancies). There was one neonatal death in a preterm infant (34 completed
227 weeks of gestation) from a pregnant woman with vaginal bleeding in the third trimester.¹⁸
228 Preterm birth occurred in 28.7% (45/157) among those with available information on
229 gestational age. Approximately 16% of preterm births were spontaneous due to PROM⁵,
230 ^{18, 29, 31, 36} or spontaneous onset of labor,¹⁴ but in most cases, it is unclear whether these
231 were spontaneous or iatrogenic. In Portugal, the eight deliveries resulted in eight live
232 births and preterm birth occurred in 25% (2/8) of them.

233 Although all breast milk samples from COVID-19 infected mothers have tested negative
234 for the SARS-CoV-2 virus, most infants did not receive breast milk.

235

236 **Comment**

237 There is no evidence that the risk of infection with COVID-19 in pregnant women is
238 greater than in the general population.^{7, 37} However, the incidence of infection in pregnant
239 women is unknown, as screening tests were not generally used, except in the presence of
240 symptoms. In a New York's hospital that implemented universal SARS-CoV-2 testing in

241 all pregnant women admitted for delivery, 15.4% of them were positive for SARS-CoV-
242 2, but 87.9% were asymptomatic.³⁸

243 Although most of the published cases confirm the absence of transmission of the SARS-
244 CoV-2 virus antenatally or intrapartum, at least when the infection occurs in the third
245 trimester of pregnancy,^{5, 11, 13, 15, 18-26} emerging evidence has suggested that vertical
246 transmission is possible.^{21, 24, 25, 27-29} However, the evidence is still limited to a reduced
247 number of reported cases, large variability in the type of biological material analyzed and
248 the time of its collection. Even if vertical transmission occurred in the reported cases, the
249 proportion would be low, below 5% of the published cases.

250 Regarding the effect of the SARS-CoV-2 virus on the fetus, no congenital malformation
251 has been reported so far and the association of COVID-19 and fetal malformation seems
252 unlikely considering the reduced risk of intrauterine infection.³⁷

253 Higher risk of fetal distress and preterm births have been reported, but it is unclear if
254 preterm birth occurs spontaneously (spontaneous onset of labor or following PROM) or
255 is iatrogenic. The evidence related to the effect of COVID-19 on pregnant women is still
256 limited. The clinical characteristics of COVID-19 were similar to those described in non-
257 pregnant women, suggesting that the prognosis is not worse in pregnant women, although
258 the number of cases studied is still reduced.^{5, 18, 31-34} A recent systematic review
259 summarized the clinical manifestations of 108 pregnant women confirmed with COVID-
260 19 and most of them presented fever (68%) and coughing (34%), and lymphocytopenia
261 (59%) with elevated C-reactive protein (70%).³⁹

262 The maternal and neonatal outcomes observed so far are quite different from the two most
263 serious coronavirus-related previous epidemics.^{7, 40-53} The first also appeared in China, in
264 2002-03, and was characterized by severe respiratory infections caused by the Severe
265 Acute Respiratory Syndrome-Coronavirus (SARS-CoV). The second occurred in 2012,

266 initially in the Middle East, the Middle East Respiratory Syndrome - Coronavirus
267 (MERS-CoV).^{7, 40} These epidemics have demonstrated the ability of coronavirus to cause
268 serious complications during pregnancy,^{43, 53} with worse prognosis in pregnant women
269 than non-pregnant women.^{42, 54}

270 In the 2002 epidemic, 12 pregnant women were infected with SARS-CoV, with a fatality
271 rate of 25%.⁵³ Among the seven pregnant women infected in the first trimester, four had
272 a miscarriage.⁵³ Two of the five pregnant women infected during the second or third
273 trimester had fetal growth restriction and four had a preterm delivery (one spontaneous;
274 three induced by the maternal condition).⁵³ In a review of the pregnancy outcomes of 11
275 women infected with MERS-CoV, seven pregnant women required admission to the
276 intensive care unit and three died, of which only one had one comorbidity (asthma). Two
277 fetal deaths occurred, and three of nine newborns were preterm.⁴³

278 However, considering that SARS-CoV-2 has genetic homology and some clinical
279 similarities to SARS-CoV and MERS-CoV, and the immunological and physiological
280 changes that occur during pregnancy, such as in cell-mediated immunity or lung function,
281 that affect both the susceptibility and the clinical severity of pneumonia, it is important
282 to pay particular attention to the monitoring of pregnant women with COVID-19, because
283 maternal and perinatal adverse outcomes are potentially relevant.^{7, 40} Although there were
284 no maternal deaths described, possible maternal deaths were reported in social media, but
285 without any robust evidence.³⁷ Furthermore, one study reported two asymptomatic
286 pregnant women at admission for delivery that rapidly evolved to severe COVID-19
287 disease requiring admission to an intensive care unit.¹²

288 Thus, it is essential to prevent the infection of COVID-19 and any other viral respiratory
289 infection, as these infections represent an increased risk for the pregnant woman and for

290 the pregnancy itself.^{7, 55, 56} It is therefore extremely important that pregnant women adopt
291 preventive actions for COVID-19 with great intensity.³⁷

292 For pregnant women with suspected or confirmed infection with SARS-CoV-2,
293 recommendations for health professionals and services have already been published.^{37, 55,}

294 ⁵⁷⁻⁵⁹ In Portugal, we can estimate that about 80,000 pregnant women are exposed to the
295 pandemic at different gestational ages, which represents an important challenge for
296 individual and public health, to avoid infection in this population that should be
297 considered at higher risk.

298 Most women in this review had a cesarean section, many of them without a clear medical
299 indication. The decision on the type of delivery in pregnant women with suspected or
300 confirmed infection with COVID-19 should take into account the maternal and fetal
301 clinical characteristics, as in normal practice, and not the diagnosis of COVID-19
302 infection per se. Thus, there is no obstetric contraindication to any mode of delivery,
303 unless the pregnant woman's clinical condition implies an emergent decision.³⁷

304 The limited scientific knowledge currently available makes it difficult to develop specific
305 breastfeeding recommendations. There is not enough scientific evidence to unequivocally
306 state that there is no possibility that mothers with COVID-19 can transmit the virus
307 through breast milk.⁵⁵ Therefore, recommendations should be based on the available data
308 ^{5, 15, 16, 20-22, 28} and the analogy with past circumstances and predictable costs and benefits.

309 Breastfeeding is recognized as the best form of child feeding due to the countless benefits
310 for both the mother and the newborn, including the protection against gastrointestinal and
311 respiratory infections.⁶⁰ Thus, considering the benefits of breastfeeding and the fact that
312 the transmission of other respiratory viruses is insignificant through breast milk, there is
313 no indication to stop breastfeeding. According to the recommendations of
314 WHO/UNICEF⁶¹ and the Center for Disease Control and Prevention (CDC) of the United

315 States,⁵⁵ women with suspected or confirmed infection with COVID-19 can initiate or
316 continue breastfeeding as long as clinical conditions permit. The CDC indicates that the
317 decision to initiate or continue breastfeeding must be determined by the mother with
318 COVID-19, together with family members and health professionals.⁵⁵

319 Limitations of this systematic review should be acknowledged. Considerable
320 heterogeneity was observed across the studies, which did not allow us to conduct a meta-
321 analysis. On the other hand, we cannot guarantee that we were able to identify all the
322 cases of pregnant women described in the literature. Possibly there are additional cases
323 currently presented in other types of publications, such as reports. Also, considering the
324 importance of summarizing all existing cases, we did not assess the quality of the studies
325 included in this review. Several studies had missing outcome data and selective reporting
326 bias could not be excluded. Additionally, there may be some cases which could be
327 duplicated, namely the studies which did not describe clinical characteristics case by
328 case.^{30, 33, 34, 36}

329

330 **Conclusion**

331 According to this review, fetal distress and preterm delivery seem to be more frequent
332 among pregnant women with COVID-19. There is emerging evidence on possible vertical
333 transmission (four positive results in the neonatal oral swabs for SARS-CoV-2 were
334 reported and three newborns had high values of IgM antibodies), but the clinical relevance
335 of the fetal infection is unclear. None of the first eight infants born in Portugal tested
336 positive for the SARS-CoV-2. So far, there is no evidence that the SARS-CoV-2 virus is
337 transmitted through breast milk. Maternal deaths were not reported and hospitalizations
338 in intensive care were uncommon. Although the complications appear to be similar to
339 those of non-pregnant women, services must be prepared to attend to complications,

340 especially in pregnant women with comorbidities. Therefore, pregnant women and
341 newborns should be considered particularly vulnerable populations regarding COVID-19
342 prevention and management strategies. Information, counseling and adequate monitoring
343 are essential to prevent major adverse effects of SARS-CoV-2 infection during
344 pregnancy.

361 **Acknowledgment**

362 The authors are grateful to the health professionals who provided and confirmed the cases
363 of pregnant women diagnosed with COVID-19 in Portugal: Alcides Pereira, Alexandra
364 Almeida, Alexandrina Portela, Almerinda Pereira, Anselmo Costa, Gabriela Mimoso,
365 Pedro Vieira da Silva, Rosalina Barroso, Teresa Rodrigues, Teresa Tomé.

366

367 **Authors' contributions**

368 Carina Rodrigues and Henrique Barros: Conceptualization, Original draft preparation.
369 Inês Baía and Rosa Domingues: Methodology, Data curation, Writing-Reviewing, and
370 Editing. All authors read and approved the final manuscript.

371 **References**

372

- 373 1. HUI DS, E IA, MADANI TA, et al. The continuing 2019-nCoV epidemic threat of
374 novel coronaviruses to global health - The latest 2019 novel coronavirus
375 outbreak in Wuhan, China. *Int J Infect Dis* 2020;91:264-66.
- 376 2. CALDAS JP, TAVARES M. Epidemiologia da COVID-19. 2020. [Internet]. [cited
377 2020 Apr 13] Available from:
378 [http://asset.youoncdn.com/ab296ab30c207ac641882479782c6c34/070b44658f5](http://asset.youoncdn.com/ab296ab30c207ac641882479782c6c34/070b44658f5569888804a14826ae273c.pdf)
379 [569888804a14826ae273c.pdf](http://asset.youoncdn.com/ab296ab30c207ac641882479782c6c34/070b44658f5569888804a14826ae273c.pdf)
- 380 3. CHEN N, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of
381 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
382 study. *Lancet* 2020;395:507-13.
- 383 4. RUSSELL TW, HELLEWELL J, JARVIS CI, et al. Estimating the infection and case
384 fatality ratio for COVID-19 using age-adjusted data from the outbreak on the
385 Diamond Princess cruise ship. *medRxiv* 2020:2020.03.05.20031773.
- 386 5. CHEN H, GUO J, WANG C, et al. Clinical characteristics and intrauterine vertical
387 transmission potential of COVID-19 infection in nine pregnant women: a
388 retrospective review of medical records. *The Lancet* 2020.
- 389 6. QIAO J. What are the risks of COVID-19 infection in pregnant women? *The*
390 *Lancet*.
- 391 7. RASMUSSEN SA, SMULIAN JC, LEDNICKY JA, WEN TS, JAMIESON DJ.
392 Coronavirus Disease 2019 (COVID-19) and Pregnancy: What obstetricians need
393 to know. *Am J Obstet Gynecol* 2020.
- 394 8. FAVRE G, POMAR L, MUSSO D, BAUD D. 2019-nCoV epidemic: what about
395 pregnancies? *Lancet* 2020;395:e40.

- 396 9. LIBERATI A, ALTMAN DG, TETZLAFF J, et al. The PRISMA statement for
397 reporting systematic reviews and meta-analyses of studies that evaluate health
398 care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
- 399 10. MOHER D, SHAMSEER L, CLARKE M, et al. Preferred reporting items for
400 systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
401 Syst Rev 2015;4:1.
- 402 11. IQBAL SN, OVERCASH R, MOKHTARI N, et al. An Uncomplicated Delivery in a
403 Patient with Covid-19 in the United States. N Engl J Med 2020.
- 404 12. BRESLIN N, BAPTISTE C, MILLER R, et al. COVID-19 in pregnancy: early
405 lessons. Am J Obstet Gynecol 2020:100111.
- 406 13. LEE DH, LEE J, KIM E, WOO K, PARK HY, AN J. Emergency cesarean section on
407 severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) confirmed
408 patient. Korean J Anesthesiol 2020.
- 409 14. ZAMBRANO LI, FUENTES-BARAHONA IC, BEJARANO-TORRES DA, et al. A
410 pregnant woman with COVID-19 in Central America. Travel Med Infect Dis
411 2020:101639.
- 412 15. KALAFAT E, YAPRAK E, CINAR G, et al. Lung ultrasound and computed
413 tomographic findings in pregnant woman with COVID-19. Ultrasound Obstet
414 Gynecol 2020.
- 415 16. GIDLÖF S, SAVCHENKO J, BRUNE T, JOSEFSSON H. COVID-19 in pregnancy with
416 comorbidities: More liberal testing strategy is needed. Acta Obstet Gynecol
417 Scand 2020.
- 418 17. LIU D, LI L, WU X, et al. Pregnancy and Perinatal Outcomes of Women With
419 Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis. AJR
420 Am J Roentgenol 2020:1-6.

- 421 18. ZHU H, WANG L, FANG C, et al. Clinical analysis of 10 neonates born to mothers
422 with 2019-nCoV pneumonia. *Transl Pediatr* 2020;9:51-60.
- 423 19. WANG X, ZHOU Z, ZHANG J, ZHU F, TANG Y, SHEN X. A case of 2019 Novel
424 Coronavirus in a pregnant woman with preterm delivery. *Clin Infect Dis* 2020.
- 425 20. LI Y, ZHAO R, ZHENG S, et al. Lack of Vertical Transmission of Severe Acute
426 Respiratory Syndrome Coronavirus 2, China. *Emerg Infect Dis* 2020;26.
- 427 21. WANG S, GUO L, CHEN L, et al. A case report of neonatal COVID-19 infection in
428 China. *Clin Infect Dis* 2020.
- 429 22. FAN C, LEI D, FANG C, et al. Perinatal Transmission of COVID-19 Associated
430 SARS-CoV-2: Should We Worry? *Clin Infect Dis* 2020.
- 431 23. LIAO X, YANG H, KONG J, YANG H. Chest CT Findings in a Pregnant Patient
432 with 2019 Novel Coronavirus Disease. *Balkan Med J* 2020.
- 433 24. YU N, LI W, KANG Q, et al. Clinical features and obstetric and neonatal
434 outcomes of pregnant patients with COVID-19 in Wuhan, China: a
435 retrospective, single-centre, descriptive study. *Lancet Infect Dis* 2020.
- 436 25. LIU W, WANG Q, ZHANG Q, et al. Coronavirus Disease 2019 (COVID-19)
437 During Pregnancy: A Case Series. *Preprints* 2020.
- 438 26. CHEN S, HUANG B, LUO DJ, et al. [Pregnant women with new coronavirus
439 infection: a clinical characteristics and placental pathological analysis of three
440 cases]. *Zhonghua Bing Li Xue Za Zhi* 2020;49:E005.
- 441 27. ZENG H, XU C, FAN J, et al. Antibodies in Infants Born to Mothers With
442 COVID-19 Pneumonia. *Jama* 2020.
- 443 28. DONG L, TIAN J, HE S, et al. Possible Vertical Transmission of SARS-CoV-2
444 From an Infected Mother to Her Newborn. *Jama* 2020.

- 445 29. ZENG L, XIA S, YUAN W, et al. Neonatal Early-Onset Infection With SARS-
446 CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China.
447 JAMA Pediatr 2020.
- 448 30. ZHANG L, JIANG Y, WEI M, et al. [Analysis of the pregnancy outcomes in
449 pregnant women with COVID-19 in Hubei Province]. Zhonghua Fu Chan Ke Za
450 Zhi 2020;55:E009.
- 451 31. LIU Y, CHEN H, TANG K, GUO Y. Clinical manifestations and outcome of SARS-
452 CoV-2 infection during pregnancy. J Infect 2020.
- 453 32. CHEN S, LIAO E, SHAO Y. Clinical analysis of pregnant women with 2019 novel
454 coronavirus pneumonia. J Med Virol 2020.
- 455 33. CHEN R, ZHANG Y, HUANG L, CHENG BH, XIA ZY, MENG QT. Safety and
456 efficacy of different anesthetic regimens for parturients with COVID-19
457 undergoing Cesarean delivery: a case series of 17 patients. Can J Anaesth 2020.
- 458 34. LIU H, LIU F, LI J, ZHANG T, WANG D, LAN W. Clinical and CT imaging features
459 of the COVID-19 pneumonia: Focus on pregnant women and children. J Infect
460 2020.
- 461 35. XIA H, ZHAO S, WU Z, LUO H, ZHOU C, CHEN X. Emergency Caesarean delivery
462 in a patient with confirmed coronavirus disease 2019 under spinal anaesthesia.
463 Br J Anaesth 2020.
- 464 36. LI N, HAN L, PENG M, et al. Maternal and neonatal outcomes of pregnant women
465 with COVID-19 pneumonia: a case-control study. medRxiv
466 2020:2020.03.10.20033605.
- 467 37. ROYAL COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS,
468 ROYAL COLLEGE OF MIDWIVES, ROYAL COLLEGE OF PAEDIATRICS
469 AND CHILD HEALTH, PUBLIC HEALTH ENGLAND AND HEALTH

- 470 PROTECTION SCOTLAND (2020). Coronavirus (COVID-19) Infection in
471 Pregnancy: Information for healthcare professionals (Version 8). [Internet].
472 [cited 2020 Apr 9] Available from:
473 [https://www.rcog.org.uk/globalassets/documents/guidelines/2020-04-17-](https://www.rcog.org.uk/globalassets/documents/guidelines/2020-04-17-coronavirus-covid-19-infection-in-pregnancy.pdf)
474 [coronavirus-covid-19-infection-in-pregnancy.pdf](https://www.rcog.org.uk/globalassets/documents/guidelines/2020-04-17-coronavirus-covid-19-infection-in-pregnancy.pdf)
- 475 38. SUTTON D, FUCHS K, D'ALTON M, GOFFMAN D. Universal Screening for SARS-
476 CoV-2 in Women Admitted for Delivery. *N Engl J Med* 2020.
- 477 39. ZAIGHAM M, ANDERSSON O. Maternal and Perinatal Outcomes with COVID-19:
478 a systematic review of 108 pregnancies. *Acta Obstet Gynecol Scand* 2020.
- 479 40. SCHWARTZ DA, GRAHAM AL. Potential Maternal and Infant Outcomes from
480 (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from
481 SARS, MERS, and Other Human Coronavirus Infections. *Viruses* 2020;12.
- 482 41. STOCKMAN LJ, LOWTHER SA, COY K, SAW J, PARASHAR UD. SARS during
483 pregnancy, United States. *Emerg Infect Dis* 2004;10:1689-90.
- 484 42. MAXWELL C, MCGEER A, TAI KFY, SERMER M. No. 225-Management
485 Guidelines for Obstetric Patients and Neonates Born to Mothers With Suspected
486 or Probable Severe Acute Respiratory Syndrome (SARS). *J Obstet Gynaecol*
487 *Can* 2017;39:e130-e37.
- 488 43. ALFARAJ SH, AL-TAWFIQ JA, MEMISH ZA. Middle East Respiratory Syndrome
489 Coronavirus (MERS-CoV) infection during pregnancy: Report of two cases &
490 review of the literature. *J Microbiol Immunol Infect* 2019;52:501-03.
- 491 44. ALSEREHI H, WALI G, ALSHUKAIRI A, ALRADDADI B. Impact of Middle East
492 Respiratory Syndrome coronavirus (MERS-CoV) on pregnancy and perinatal
493 outcome. *BMC Infect Dis* 2016;16:105.

- 494 45. ASSIRI A, ABEDI GR, AL MASRI M, BIN SAEED A, GERBER SI, WATSON JT.
495 Middle East Respiratory Syndrome Coronavirus Infection During Pregnancy: A
496 Report of 5 Cases From Saudi Arabia. *Clin Infect Dis* 2016;63:951-53.
- 497 46. HAINES CJ, CHU YW, CHUNG TK. The effect of Severe Acute Respiratory
498 Syndrome on a hospital obstetrics and gynaecology service. *Bjog* 2003;110:643-
499 5.
- 500 47. JEONG SY, SUNG SI, SUNG JH, et al. MERS-CoV Infection in a Pregnant Woman
501 in Korea. *J Korean Med Sci* 2017;32:1717-20.
- 502 48. JIANG X, GAO X, ZHENG H, et al. Specific immunoglobulin g antibody detected
503 in umbilical blood and amniotic fluid from a pregnant woman infected by the
504 coronavirus associated with severe acute respiratory syndrome. *Clin Diagn Lab*
505 *Immunol* 2004;11:1182-4.
- 506 49. MALIK A, EL MASRY KM, RAVI M, SAYED F. Middle East Respiratory
507 Syndrome Coronavirus during Pregnancy, Abu Dhabi, United Arab Emirates,
508 2013. *Emerg Infect Dis* 2016;22:515-7.
- 509 50. OWOLABI T, KWOLEK S. Managing obstetrical patients during severe acute
510 respiratory syndrome outbreak. *J Obstet Gynaecol Can* 2004;26:35-41.
- 511 51. PAYNE DC, IBLAN I, ALQASRAWI S, et al. Stillbirth during infection with Middle
512 East respiratory syndrome coronavirus. *J Infect Dis* 2014;209:1870-2.
- 513 52. ROBERTSON CA, LOWTHER SA, BIRCH T, et al. SARS and pregnancy: a case
514 report. *Emerg Infect Dis* 2004;10:345-8.
- 515 53. WONG SF, CHOW KM, LEUNG TN, et al. Pregnancy and perinatal outcomes of
516 women with severe acute respiratory syndrome. *Am J Obstet Gynecol*
517 2004;191:292-7.

- 518 54. LAM CM, WONG SF, LEUNG TN, et al. A case-controlled study comparing
519 clinical course and outcomes of pregnant and non-pregnant women with severe
520 acute respiratory syndrome. *Bjog* 2004;111:771-4.
- 521 55. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC).
522 Pregnancy & Breastfeeding: Information about Coronavirus Disease 2019.
523 [Internet]. [cited 2020 Apr 9] Available from:
524 [https://www.cdc.gov/coronavirus/2019-ncov/prepare/pregnancy-](https://www.cdc.gov/coronavirus/2019-ncov/prepare/pregnancy-breastfeeding.html)
525 [breastfeeding.html](https://www.cdc.gov/coronavirus/2019-ncov/prepare/pregnancy-breastfeeding.html)
- 526 56. YANG H, WANG C, POON LC. Novel coronavirus infection and pregnancy.
527 *Ultrasound Obstet Gynecol* 2020.
- 528 57. FAVRE G, POMAR L, QI X, NIELSEN-SAINES K, MUSSO D, BAUD D. Guidelines
529 for pregnant women with suspected SARS-CoV-2 infection. *Lancet Infect Dis*
530 2020.
- 531 58. POON LC, YANG H, LEE JCS, et al. ISUOG Interim Guidance on 2019 novel
532 coronavirus infection during pregnancy and puerperium: information for
533 healthcare professionals. *Ultrasound Obstet Gynecol* 2020.
- 534 59. LIANG H, ACHARYA G. Novel corona virus disease (COVID-19) in pregnancy:
535 What clinical recommendations to follow? *Acta Obstet Gynecol Scand* 2020.
- 536 60. VICTORA CG, BAHL R, BARROS AJ, et al. Breastfeeding in the 21st century:
537 epidemiology, mechanisms, and lifelong effect. *Lancet* 2016;387:475-90.
- 538 61. UNICEF/WORLD HEALTH ORGANIZATION. Coronavirus disease (COVID-
539 19): What parents should know. [Internet]. [cited 2020 Apr 9] Available from:
540 <https://www.unicef.org/stories/novel-coronavirus-outbreak-what-parents-should-know>
- 541 62. Luo Y, Yin K. Management of pregnant women infected with COVID-19.
542 *Lancet Infect Dis* 2020.

- 543 63. ZHANG B, LIU S, TAN T, et al. Treatment with convalescent plasma for critically
544 ill patients with SARS-CoV-2 infection. Chest 2020.
- 545 64. WEN R, SUN Y, XING QS. A patient with SARS-CoV-2 infection during
546 pregnancy in Qingdao, China. J Microbiol Immunol Infect 2020.
- 547

548 **Table 1. Characteristics of pregnant women diagnosed with COVID-19 described in**
 549 **the literature (n=212).**

550

	n/N (%)
Maternal characteristics	
Age, years (min-max)	22-43
Country of hospital admission	
China	200/212 (94.3)
United States of America	8/212 (3.8)
South Korea	1/212 (0.5)
Honduras	1/212 (0.5)
Turkey	1/212 (0.5)
Sweden	1/212 (0.5)
Pregnancy complications	
Fetal distress	20/212 (9.4)
Gestational diabetes	13/212 (6.1)
Gestational hypertension	11/212 (5.2)
PROM	7/212 (3.3)
Anemia	5/212 (2.4)
Placenta previa/bleeding	5/212 (2.4)
Preeclampsia	4/212 (1.9)
Hypothyroidism	4/212 (1.9)
Chronic hypertension	3/212 (1.4)
Thalassemia	2/212 (0.9)
Polycystic ovary syndrome	2/212 (0.9)
Cholecystitis	2/212 (0.9)
Asthma	2/212 (0.9)
Diabetes mellitus type 2	2/212 (0.9)
Placental abruption	1/212 (0.5)
Oligohydramnios	1/212 (0.5)
Polyhydramnios	1/212 (0.5)
Hepatitis B infection	1/212 (0.5)
Mitral valve and tricuspid valve replacement	1/212 (0.5)
Pregnancy characteristics/outcomes	
Pregnant women at discharge (undelivered)	30/212 (14.2)
Multiple pregnancies	4/212 (1.9)
Deliveries	182/212 (85.8)
Multiple pregnancies delivered	4/182 (2.2)
Stillbirths	1/186 (0.5)

Live births	185/186 (99.5)
Cesarean section	139/158 (88.0)
Preterm birth (<37 weeks of gestation)	45/157 (28.7)
Maternal outcomes	
Maternal deaths	0/212 (0.0)
Maternal admission to Intensive Care Unit	4/212 (1.9)
Neonatal outcomes	
Neonatal deaths	1/185 (0.5)
SARS-CoV-2 infection confirmed by oral swabs	4/185 (2.2)
High levels of SARS-CoV-2 IgM antibodies	3/185 (1.6)
Type of intrauterine/ neonatal samples collected and results	
Placenta	21/186 (11.3)
Positive results	0/21 (0.0)
Cord blood	13/186 (7.0)
Positive results	0/13 (0.0)
Amniotic fluid	14/186 (7.5)
Positive results	0/14 (0.0)
Newborn's oral swabs	70/185 (33.8)
Positive results	4/70 (5.7)
Measurement of SARS-CoV-2 IgM and IgG antibody	7/185 (3.8)
Reactive IgM	3/7 (42.8)
Reactive IgG	6/7 (85.7)
Breast milk	13/185 (7.0)
Positive results	0/13 (0.0)

551

552

553 **Table 2. Characteristics of COVID-19 positive women delivered in Portugal, until**
554 **the 31st of March 2020.**

555

Case	Local	Sex	Gestation al age	Type of delivery	Birth weight (grams)	SARS-CoV-2 confirmed on the infant
1	Porto	Female	38	Instrumental vaginal (vacuum)	3240	Negative
2	Porto	Male	40	Cesarean	3110	Negative
3	Lisboa	Male	30	Cesarean	1530	Negative
4	Porto	Male	40	Vaginal	4050	Negative
5	Braga	Male	36	Cesarean	2940	Negative
6	Matosinhos	Female	39	Cesarean	2480	Negative
7	Lisboa	Female	40	Cesarean	3005	Negative
8	Amadora	Male	39	Cesarean	3300	Negative

556